There are 3163 resources available
361P - PALVEN: A phase Ib study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
Presenter: Christine Muttiah
Session: Poster session 14
362P - Dose reductions due to treatment-related side effects and survival outcomes in breast cancer patients treated with CDK4/6 Inhibitors
Presenter: Pinar Kubilay Tolunay
Session: Poster session 14
363P - Palbociclib exposure in relation to response and toxicity in patients with advanced breast cancer
Presenter: Sanne Buijs
Session: Poster session 14
364P - Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
Presenter: Eva Ciruelos
Session: Poster session 14
365P - Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Mafalda Oliveira
Session: Poster session 14
366P - Exploring the benefit of combining paclitaxel with capivasertib treatment in PI3K/AKT/PTEN-altered and non-altered TNBC preclinical models
Presenter: Cath Eberlein
Session: Poster session 14
367P - Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER+ metastatic breast cancer
Presenter: Ezra Rosen
Session: Poster session 14
368P - Tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR+/HER2- advanced breast cancer after CDK4/6 inhibitors: Preliminary findings of a multi-center, phase II study
Presenter: Qiufan Zheng
Session: Poster session 14
370P - A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects
Presenter: Pin Zhang
Session: Poster session 14